Background {#S1}
==========

Meningiomas are commonly benign tumors with a generally favorable prognosis ([@B1]). However, without treatment they may progress locally, compressing adjacent structures and causing neurologic deficits. They pose a unique clinical challenge due to their large size and variable anatomical locations within the skull ([@B1]). Surgical resection of the entire tumor, when possible without neurologic injury, is the standard of care with a 10-year local control of 80% or higher ([@B2][@B3][@B4][@B5][@B6][@B7][@B8]--[@B9]). For subtotally resected or recurrent tumors, conventionally fractionated radiation therapy (1.8--2.0 Gy per fraction) to approximately 54 Gy improves local control ([@B2], [@B4], [@B6][@B7]--[@B8]).

More recent experience suggests a role for single fraction stereotactic radiosurgery (SRS) (12--18 Gy) as a primary treatment for well selected, small meningiomas or as adjuvant treatment for residual disease ([@B10][@B11]--[@B12]). In cases where single fraction SRS has been appropriately utilized, results have been excellent, demonstrating equivalent local control to both conventional radiation therapy and surgical resection for select groups of meningioma patients ([@B10], [@B11]). Patients with large tumors (\>7.5 cc) have a poor prognosis with this approach, and unacceptably high rates of local failure ([@B10], [@B11]).

Single fraction radiosurgery, however, may increase the risk of symptomatic peritumoral edema and/or cranial nerve injury ([@B10], [@B12], [@B13]). This risk of peritumoral edema may be increased in tumors that are large, recurrent, adjacent to large veins, and/or basally located ([@B10], [@B13][@B14][@B15][@B16][@B17][@B18]--[@B19]). Conventional fractionated radiation therapy has been employed to treat these patients. The gross tumor volume (GTV) is typically targeted with a margin of 2--5 mm to adjust for set-up inaccuracy. Due to these large planned treatment volumes (PTVs), treatment is generally fractionated over 25--30 sessions to limit toxicity to adjacent normal structures. Due to the long natural history of this disease, it is essential to maximize post-treatment quality of life by preventing treatment related adverse outcomes while minimizing neurological symptoms associated with tumor progression. It is possible that some of the adverse effects of single fraction radiosurgery for large tumors may be mitigated by limited fractionation.

The CyberKnife is an image-guided, frameless, SRS platform. The frameless configuration allows for staged treatment, and it has been successfully utilized to treat a wide variety of intracranial tumors including meningiomas ([@B8], [@B9], [@B20]). In this retrospective study, we report our preliminary results with five fraction image-guided radiosurgery as a treatment for meningiomas, either as monotherapy or as an adjuvant to surgical resection. This treatment was conducted with the belief that its accurate and highly conformal delivery would minimize peritumoral edema and cranial nerve toxicity.

Materials and Methods {#S2}
=====================

Patient selection and treatment {#S2-1}
-------------------------------

We performed a retrospective review of patients with benign meningiomas treated with CyberKnife SRS from December 1st, 2007 to February 1st, 2011 by SPC and BTC. Patients who had undergone SRS for intracranial meningiomas with or without surgical resection were included in the present study. Patients with atypical or malignant meningiomas were excluded from this study. All patients were treated by an interdisciplinary team of radiation oncologists and neurosurgeons. High resolution CT images were obtained from all patients for pre-treatment planning with target volumes, and critical structures were manually delineated by the treating neurosurgeon (Figure [1](#F1){ref-type="fig"}). The treating isodose and prescription dose were determined by the treating radiation oncologist in consultation with the treating neurosurgeon, and took into account the target volume, proximity to critical structures, and previous treatment history. In most cases, the dose was prescribed to the isodose surface that encompassed the margin of the tumor. Treatment plans were generated using an inverse planning method by the CyberKnife treatment software (Multiplan, Accuray).

![**Fifty-three-year-old man with a right Meckel cave meningioma**. He presented with right facial pain. The decision was to proceed with radiosurgery. Treatment planning axial **(A)** and sagittal **(B)** computed tomography images demonstrating the GTV (red), brainstem (blue), and chiasm (yellow). Isodose lines shown as follows: blue 79% (prescription) and purple 50%. Note proximity of the meningioma to the brainstem. The tumor was treated with 2500 cGy in five fractions and his pain resolved.](fonc-03-00213-g001){#F1}

Outcomes assessment {#S2-2}
-------------------

Patients were tracked as part of routine clinical follow-up by the interdisciplinary team. MRI scans were obtained at pre-defined intervals, every 6 months for the first year, and then yearly thereafter, unless acute changes in neurological status warranted immediate imaging. Neurological symptoms were clinically assessed and recorded by the treating neurosurgeons. Peritumoral edema was assessed on T2 weighted and FLAIR MRI sequences. Patient steroid requirements were assessed at each clinical follow-up visit.

Statistical analysis {#S2-3}
--------------------

All statistical analyses were performed utilizing SPSS Statistics v19 (IBM). Statistical analysis was performed in order to identify pre-treatment and treatment variables that correlated with post-treatment peritumoral edema. Due to the relatively small sample size, Fisher's Exact Test was used for categorical variables, while Spearman's Rho was employed for examining the interaction between continuous variables and post-treatment peritumoral edema. For analysis of volume and dose, due to the small sample sizes, patients were stratified as being over or under the median and a Chi-square test was employed. Alpha was set to 0.05 to yield a 95% confidence interval (CI) for all statistical tests.

Results {#S3}
=======

Patient and treatment characteristics {#S3-4}
-------------------------------------

Thirty-eight patients were identified as having undergone treatment for intracranial meningiomas and were subsequently included in the current study (Table [1](#T1){ref-type="table"}). Twenty-nine (79%) of the patients were female and nine (24%) were male. The median age at time of treatment with radiosurgery was 64 years. Thirteen (34%) patients had undergone prior surgery, of which five were classified as gross total resection and eight were classified as subtotal resections. The remaining 24 patients had received no previous surgical or non-surgical interventions and were treated without pathologic confirmation. Twenty-seven (71%) of the tumors were primary, while 11 (29%) were recurrent. The tumors occurred at a variety of intracranial sites (Table [2](#T2){ref-type="table"}), with an almost even number of basal and non-basal tumors, 22 (58%) and 16 (42%) respectively. The median tumor volume was 3.83 mm^3^ (range, 1.08--20.79 mm^3^). The median isodose was 82% (70--90%) which was treated with a median prescription dose of 2500 cGy (2500--3500 cGy) and resulted in a median percent tumor coverage of 99.5% (Table [3](#T3){ref-type="table"}).

###### 

**A summary of patient characteristics for patients included in the study**.

  Characteristic        *N* = 38   (%)
  --------------------- ---------- --------
  Race/ethnicity                   
   Caucasian            24         \(63\)
   African American     11         \(29\)
   Hispanic             1          \(3\)
   Asian                2          \(5\)
  Gender                           
   Female               29         \(76\)
   Male                 9          \(24\)
  Age at radiosurgery              
   Mean                 62         
   Median               64         
  Extent of resection              
   Gross total          5          \(13\)
   Subtotal             8          \(21\)
   No surgery           24         \(63\)

###### 

**A summary of tumor characteristics for all tumors included within the study**.

  Characteristic            *N* = 38   (%)
  ------------------------- ---------- --------
  Primary vs. recurrent                
   Primary                  27         \(71\)
   Recurrent                11         \(29\)
  Location: general                    
   Basal                    22         \(58\)
   Non-basal                16         \(42\)
  Location: specific                   
   Bifrontal                1          \(3\)
   Cavernous sinus          7          \(18\)
   Cerebellopontine angle   5          \(13\)
   Falcine                  2          \(5\)
   Falcotentorial           1          \(3\)
   Lateral ventricle        1          \(3\)
   Meckel's cave            2          \(5\)
   Middle cranial fossa     1          \(3\)
   Parafalcine              2          \(5\)
   Parasagittal             5          \(13\)
   Parietal convexity       1          \(3\)
   Parietal lobe            1          \(3\)
   Petroclival              2          \(5\)
   Posterior fossa          1          \(3\)
   Sphenoid wing            2          \(5\)
   Suprasellar              1          \(3\)
   Temporal lobe            3          \(8\)
  Volume (cc)                          
   Min                      1.08       
   Max                      20.79      
   Mean                     6.22       
   Median                   3.84       

###### 

**A summary of treatment characteristics for patients treated on a frameless stereotactic radiosurgical system**.

  Characteristic           *N* = 38   Characteristic          *N* = 38
  ------------------------ ---------- ----------------------- ----------
  Rx dose (cGy)                       Percent tumor covered   
   Min                     2500        Min                    97.4
   Max                     3500        Max                    99.9
   Mean                    2691        Mean                   99.3
   Median                  2500        Median                 99.5
  Isodose line (%)                    Non-zero beams          
   Min                     70          Min                    88
   Max                     90          Max                    259
   Mean                    82          Mean                   175
   Median                  82          Median                 174
  Homogeneity index                   Collimator (mm)         
   Min                     1           Min                    5
   Max                     1.39        Max                    15
   Mean                    1.22        Mean                   11
   Median                  1.2         Median                 10
  New conformality index                                      
   Min                     1.32                               
   Max                     2.25                               
   Mean                    1.66                               
   Median                  1.61                               

Complications and neurological symptoms after SRS {#S3-5}
-------------------------------------------------

Acute toxicity after SRS treatment included symptoms such as headaches, fatigue, and nausea. Headaches were the most common complication with nine patients (23.7%) complaining of headaches at the end of treatment. Four patients (10.5%) experienced fatigue, and only one patient (2.6%) complained of nausea. Twenty-four patients (63.2%) presented with neurological symptoms prior to therapy (Table [4](#T4){ref-type="table"}). These neurological symptoms included facial pain, hearing loss, diplopia, proptosis, vertigo, facial numbness, and reduced visual acuity. After SRS, neurological examination revealed complete resolution of neurological symptoms in 14 patients (58.3%), continued symptoms in eight patients (33.3%), and recurrence of symptoms after initial improvement in two patients (8.3%). Only one patient (2.6%) developed a new deficit, facial numbness, immediately after radiation, which resolved after a few days. Otherwise, no new neurological deficits were observed after SRS.

###### 

**A summary of changes in neurological deficits**.

  Deficit                 Pre-SRS   Improvedpost-SRS   Recurrence after initialimprovement   Continued Sx post-SRS
  ----------------------- --------- ------------------ ------------------------------------- -----------------------
  Facial pain             9         5                  2                                     2
  Hearing loss            1         0                  0                                     1
  Diplopia                4         4                  0                                     0
  Proptosis               2         0                  0                                     2
  Vertigo                 2         2                  0                                     0
  Facial numbness         4         3                  0                                     1
  Reduced visual acuity   2         0                  0                                     2

*All neurological deficits were noted by the treatment team on either clinical exam or through direct questioning of the patient*.

Facial pain was the most common presenting neurological symptom pre-SRS treatment. Of the nine patients (37.5%) who presented with facial pain, five patients (55.6%) were asymptomatic after radiation, two patients (22.2%) had continued symptoms, and another two patients (22.2%) had recurrent facial pain after initial improvement. Diplopia, vertigo, and facial numbness improved in the majority of patients. Proptosis and reduced visual acuity did not improve with treatment.

Local control rate and peritumoral edema {#S3-6}
----------------------------------------

Twenty-four patients (63.2%) who underwent SRS showed no change in tumor size, while 14 patients (36.8%) showed a decrease in tumor size resulting in a crude radiographic local control rate of 100% of the meningiomas treated with SRS (Table [5](#T5){ref-type="table"}).

###### 

**(A) A comprehensive table detailing individual patient outcomes with regards to pre-treatment therapies, radiation dosage, and subsequent clinical outcomes. (B) A summary of individual patient factors and whether patients had pre-treatment or post-treatment peritumoral edema**.

  **(A)**                                                                                                                                    
  ------------- ------------------------------ ----------------- ---------------- --------------------- ------------------------------------ -------------------------------------
  1             Temporal lobe                  None              3000             Decreased             Headache                             Yes
  2             Tentorial                      None              3500             Decreased             No                                   No
  3             Posterior Temporal lobe        Subtotal          3000             Stable                No                                   No
  4             Cavernous sinus                Subtotal          2500             Decreased             No                                   No
  5             CPA                            None              2750             Stable                No                                   No
  6             CPA                            None              2750             Stable                No                                   No
  7             Cavernous sinus                None              2500             Stable                No                                   No
  8             Cavernous sinus                None              2500             Stable                Headache                             Yes
  9             Parasagittal                   Gross total       2500             Stable                Fatigue                              No
  10            Parietal falcine               Subtotal          2500             Stable                No                                   No
  11            Parietal Parasagittal          Gross total       2500             Stable                Headache                             No
  12            Petroclival                    Subtotal          2500             Stable                Fatigue                              No
  13            Medial sphenoid wing           Subtotal          2500             Stable                Fatigue and headache                 No
  14            Middle cranial fossa           None              3000             Stable                Headache                             Yes
  15            Petroclival                    None              2500             Stable                Headache                             Yes
  16            Cavernous sinus                Subtotal          2500             Decreased             No                                   No
  17            Frontal parafalcine            None              2500             Decreased             No                                   No
  18            Sphenoid wing                  None              2500             Decreased             No                                   No
  19            CPA                            None              2500             Stable                No                                   No
  20            Parietal convexity             None              2500             Stable                No                                   No
  21            CPA                            None              2500             Stable                No                                   Yes
  22            Anterior parafalcine           None              3000             Decreased             Headache and nausea                  Yes
  23            Bifrontal                      None              3000             Stable                No                                   No
  24            CPA                            None              3000             Decreased             Headache                             No
  25            Anterior falcine               Gross total       3000             Decreased             No                                   No
  26            Cavernous sinus                None              2500             Decreased             No                                   No
  27            Falcotentorial                 Subtotal          2500             Stable                No                                   No
  28            Posterior fossa                Subtotal          3000             Stable                No                                   No
  29            Posterior Parasagittal         Gross total       2500             Stable                No                                   No
  30            Cavernous sinus                None              2500             Stable                No                                   No
  31            Parafalcine                    None              2500             Decreased             No                                   No
  32            Anterior temporal              Gross total       3000             Decreased             Headache                             Yes
  33            Lateral ventricle              None              3000             Stable                No                                   No
  34            Suprasellar                    None              2500             Stable                Fatigue                              Yes
  35            Cavernous sinus                None              2500             Decreased             Hypesthesia                          No
  36            Meckel's cave                  None              2500             Stable                No                                   No
  37            Meckel's cave                  None              2750             Decreased             No                                   No
  38            Parietal lobe                  Gross total       3000             Stable                No                                   No
                                                                                                                                             
  **(B)**                                                                                                                                    
  **Patient**   **Anatomicalclassification**   **Volume (cc)**   **Recurrence**   **Adjacentto vein**   **Pre-treatmentperitumoral edema**   **Post-treatmentperitumoral edema**
                                                                                                                                             
  1             Non-basal                      1.08              No               No                    No                                   No
  2             Non-basal                      1.6               No               Yes                   No                                   Yes
  3             Non-basal                      16.7              Yes              No                    Yes                                  Yes
  4             Basal                          5.56              Yes              Yes                   Yes                                  Yes
  5             Basal                          1.37              No               No                    No                                   No
  6             Basal                          2.56              No               Yes                   No                                   No
  7             Basal                          4.05              No               No                    No                                   No
  8             Basal                          12.19             No               No                    No                                   No
  9             Non-basal                      11.24             Yes              No                    Yes                                  Yes
  10            Non-basal                      6.48              Yes              No                    No                                   No
  11            Non-basal                      6.44              Yes              Yes                   No                                   No
  12            Basal                          2.12              Yes              No                    No                                   No
  13            Basal                          20.17             No               No                    No                                   No
  14            Basal                          2.14              No               Yes                   No                                   Yes
  15            Basal                          20.79             No               No                    No                                   No
  16            Basal                          13.82             No               Yes                   Yes                                  Yes
  17            Non-basal                      6.43              No               No                    No                                   No
  18            Basal                          5.48              No               No                    No                                   No
  19            Basal                          10.84             No               No                    No                                   No
  20            Non-basal                      3.24              No               No                    No                                   No
  21            Basal                          12.13             No               No                    No                                   Yes
  22            Non-basal                      1.17              No               No                    No                                   No
  23            Non-basal                      6.59              No               No                    No                                   No
  24            Basal                          1.53              No               No                    No                                   No
  25            Non-basal                      3.59              Yes              Yes                   Yes                                  Yes
  26            Basal                          13.07             No               No                    No                                   No
  27            Non-basal                      4.68              No               No                    No                                   No
  28            Basal                          11.83             Yes              No                    No                                   No
  29            Non-basal                      2.63              Yes              No                    No                                   Yes
  30            Basal                          2.65              No               No                    No                                   No
  31            Non-basal                      2.611             No               No                    No                                   Yes
  32            Non-basal                      3.04              Yes              Yes                   No                                   No
  33            Non-basal                      3.628             No               Yes                   No                                   No
  34            Basal                          2.62              No               No                    No                                   No
  35            Basal                          1.38              No               Yes                   No                                   No
  36            Basal                          4.97              No               No                    No                                   No
  37            Basal                          1.90              No               Yes                   No                                   No
  38            Non-basal                      1.89              Yes              Yes                   No                                   No

Intracranial edema is commonly managed with oral steroids, and oral steroid requirements were measured as a surrogate for post-radiation peritumoral edema. Symptomatic, acute, post-radiation edema requiring steroids occurred in six patients (15.8%). In addition, two patients (5.3%) were given steroids due to evidence of post-radiation edema on MRI, but without any clinical signs of toxicity (Table [5](#T5){ref-type="table"}).

Pre-SRS radiographic peritumoral edema continued to be observed in five patients (13.2%) on follow-up MRI imaging. Of these patients, four (10.5%) had recurrent tumors following a subtotal or gross resection, and three (7.9%) had a radiological tumor volume greater than 10.0 cc (Table [5](#T5){ref-type="table"}). A total of 10 patients had post-treatment radiographic peritumoral edema, with new onset being observed in five patients (13.2%). On univariate statistical analysis, only pre-treatment peritumoral edema (*p* = 0.001) and adjacency to a large vein (*p* = 0.045) correlated with post-treatment peritumoral edema (Table [6](#T6){ref-type="table"}).

###### 

**A statistical analysis of variables associated with peritumoral edema**.

  Pre-treatment characteristic      Likelihood ratio   *p*-Value
  --------------------------------- ------------------ -----------
  Pre-treatment peritumoral edema   15.77              0.001
  Anatomical classification         1.28               0.293
  Adjacent to vein                  4.83               0.045
  Volume (cc)                       0                  1
  Recurrence                        2.77               0.116
  Cumulative dose                   0.002              0.968

*p-Values are for two-sided Fisher's Exact Test*.

Discussion {#S4}
==========

Our results show that fractionated SRS may provide similar local control with minimal toxicity and excellent quality of life. Headaches, fatigue, and nausea were the only three acute complaints, all of which resolved over time. Headaches were the most common complication, present in 23.7% of our patients, which is consistent with other studies ([@B12]). Nausea was the least common, present in only one patient. This trend has also been observed in previous studies ([@B21], [@B22]).

In this study several patients presented with neurological symptoms and the majority responded to treatment with minimal toxicity at 2 years of follow-up. The present response rate of neurological symptoms compares favorably to similar studies with Gamma Knife ([@B17], [@B21]). Kondziolka et al. noted that five patients in their series of 99 cases had new or worsened deficits occurring 3--31 months after radiosurgery, while Chang et al. reported two cases out of 140 experiencing worsened deficits. Most tellingly, Kondziolka et al. reported that 67 out of 70 patients reported that their treatments were subjectively "successful" on an outcomes questionnaire, indicative of a high preservation of quality of life post-SRS ([@B21]). Uniquely, we have found an excellent response of tumor-associated facial pain to five fraction radiosurgery. While documented in other studies involving single fraction radiosurgery, our results suggest that a five fraction approach can also yield a beneficial reduction in tumor-associated trigeminal neuralgia ([@B23][@B24]--[@B25]). Other studies have suggested that recurrence of these symptoms typically occurs within 2 years, and is more likely to recur for malignant skull base tumors, with the mechanism of relief being decompression of affected nerve roots ([@B24], [@B25]).

Stereotactic radiosurgery was well tolerated with few post-treatment complications. As previously mentioned, other studies have suggested a relationship between tumor volume and post-SRS edema and complications ([@B26]). However, we found no correlation found between tumor volume, margin dose, and the presence of complications, which is similar to findings in other studies ([@B12], [@B14], [@B22]). Furthermore, it may be that if such a relationship does exist between large tumor volume and complications, that it may be mitigated in part through dose fractionation like in the present study.

At roughly 2 years, none of the patients developed local failures, and 14 showed a decrease in tumor size that may be correlated favorably with local control, although this has not been conclusively shown ([@B27]). There is a high degree of variability in volume reduction post-radiosurgery with studies reporting rates less than 20% and over 60%, ultimately the implications and the time course of post-radiosurgery volume reduction need to be further studied to ascertain its prognostic implications ([@B21], [@B28]). With regards to local control, control rates for meningiomas post-radiosurgery typically require longer follow-up for thorough assessment, with many studies placing the 10-year rate of local control at 84% ([@B11], [@B22], [@B29]).

Only 13% of the patients developed new onset post-SRS peritumoral edema, with 26% of patients developing it overall. In addition, only 2.6% of the patient group receiving five fraction radiosurgery had symptomatic peritumoral edema. These results are in agreement with other papers on the use of hypofractionated radiosurgery for meningiomas, and compares favorably to an average of 5--10% of patients developing symptomatic edema in other studies ([@B12], [@B21], [@B30], [@B31]). In one such study by Kollova et al. edema was more common in tumor volumes greater than 10 cm^3^ ([@B26]). However the present study and others have suggested that simple tumor volume is not a significant contributor to post-radiation peritumoral edema, which may be in fact more due to the interface between meningioma and cortical tissue rather than gross volume ([@B21], [@B32]).

Conclusion {#S5}
==========

Stereotactic radiosurgery is a safe and effective treatment for benign intracranial meningiomas with or without surgical resection. Dose fractionation is well tolerated, and may offer equivalent local control to single session SRS. Fractionation may offer particular benefit to patients with large tumors located in critical locations or in other high-risk patients. Further studies are warranted to fully ascertain the potential benefits and risks of dose fractionation for SRS therapy of meningiomas, and its ultimate impact on local control.
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